PRZOOM - /newswire/ -
Monrovia, CA, United States, 2012/06/29 - Phil Skolnick at NIDA, NIH to speak at 2nd Neuropsychiatric conference Sept 13-14 San Francisco, California.
Phil Skolnick, Director of the Division of Pharmacotherapies & Medical Consequences of Drug Abuse at NIDA, NIH will give a presentation on “Biological Approaches to Treat Substance Use Disorders” at the 2nd Neuropsychiatric Research and Development conference taking place on Sept 13-14, 2012 in San Francisco, CA.
Dr. Skolnick will describe passive and active immunization strategies directed against methamphetamine, nicotine, cocaine, and heroin as well as a bioengineered esterase that is capable of rapidly inactivating cocaine. Among the most compelling reasons to develop biologics is the promise of a long-lived protective effect, which requires the patient to make “one good decision” to receive a biologic, compared to one (or multiple) good daily decisions to remain compliant with a traditional medication.
His presentation will highlight:
• Recent advances in the development of biologics to treat SUDs;
• The strengths and limitations of biological approaches;
• Challenges in clinical trial design using biologics;
• Market opportunities for biologics in the treatment of SUDs.
Phil Skolnick is the Director, Division of Pharmacotherapies and Medical Consequences of Drug Abuse at the National Institute on Drug Abuse, NIH. Dr. Skolnick served as Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, Inc. He was also Research Professor of Psychiatry (2001-2009) and a member of the Center of Excellence on Drug Addiction at New York University-Langone Medical Center. Dr. Skolnick was a Lilly Research Fellow (Neuroscience) at Lilly Research Laboratories (1997-2000).
Dr. Skolnick’s awards and honors include the Experimental Therapeutics Prize from the American Society for Pharmacology and Experimental Therapeutics, an Anna Monika Prize, and the A.E. Bennett Award in Biological Psychiatry. He has twice been awarded the Doctor of Science, honoris causa. Dr. Skolnick has co authored more than 500 articles and currently serves on the editorial advisory boards of more than half a dozen journals. He is an editor of Current Protocols in Neuroscience and has edited six books, most recently, Glutamate-Based Approaches to Psychiatric Disorders (2010). The Institute of Scientific Information (ISI) has acknowledged his contributions by naming him to the elite group of “Highly Cited” authors.
GTC’s 2nd Neuropsychiatric Research and Development will discuss the latest breakthroughs, new drug targets, new models, neuroimaging, novel technologies and several other novel developments and therapeutics to combat neuropsychiatric disorders. The conference is also a part of the 2nd CNS Diseases World Summit. The Summit brings together the leading experts across the industry and academia to discuss the latest research and developments in the CNS field. The summit has four parallel tracks that focus on neurodegenerative conditions, neuropsychiatric disorders, pain research and therapeutics and CNS partneriing and deal-making.
Join your colleagues at this exciting Neuropsychiatric conference and CNS summit, and hear from and meet with key representatives in the field including Charles B. Nemeroff at University of Miami, Husseini Manji - Global Head of Neuroscience Therapeutic at Janssen, Barry Brand - Chief Executive Officer at CeNeRx, Michael W. Weiner at UCSF, George Garibaldi - Global Head of CNS Clinical Development at F. Hoffmann-La Roche, Tony W. Ho - Vice President at AstraZeneca, Michael C. Venuti, Chief Scientific Officer at NeuroTherapeutics Pharma, and many more!
For more information, please visit gtcbio.com/.